TOPLINE:

An analysis of a real-world US practice revealed that a substantial proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who initiated dupilumab remained adherent at 12 months. Among those who discontinued therapy, over 40% resumed treatment within a short timeframe.

METHODOLOGY:

Researchers used real-world administrative claims and clinical data to analyze treatment patterns of 3318 patients (mean age, 47.1 years; 54.4% men) with CRSwNP who initiated dupilumab between June 2019 and December 2021.

Persistence with dupilumab was defined as the interval from treatment initiation to either the end of a 60-day gap without a refill or a switch to another CRSwNP biologic (omalizumab or mepolizumab).

Patients were considered adherent to dupilumab if they had

See Full Page